Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study

Zacks04-24

Corcept Therapeutics Incorporated CORT announced positive data from one part of the pivotal phase III GRACE study, which evaluated its lead pipeline candidate, relacorilant, for treating patients with...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2429895145?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_LT6pKD_Fk90UGSt.TnE5Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e10425bef32c421f16ccc0d2a8c8bb61","is_english":true,"pubTime":"2024-04-24 00:12","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2429895145","market":"us","top_or_hot":-1,"title":"Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study","media":"Zacks","content":"<div>\n<p>Corcept Therapeutics Incorporated CORT announced positive data from one part of the pivotal phase III GRACE study, which evaluated its lead pipeline candidate, relacorilant, for treating patients with...</p>\n\n<a href=\"https://finance.yahoo.com/news/corcept-cort-posts-positive-data-161200336.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorcept (CORT) Posts Positive Data From Cushing's Syndrome Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-24 00:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/corcept-cort-posts-positive-data-161200336.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Corcept Therapeutics Incorporated CORT announced positive data from one part of the pivotal phase III GRACE study, which evaluated its lead pipeline candidate, relacorilant, for treating patients with...</p>\n\n<a href=\"https://finance.yahoo.com/news/corcept-cort-posts-positive-data-161200336.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CORT","symbol_name":"Corcept医疗","start_time":0,"source_url":"https://finance.yahoo.com/news/corcept-cort-posts-positive-data-161200336.html","article_id":"2429895145","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_LT6pKD_Fk90UGSt.TnE5Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e10425bef32c421f16ccc0d2a8c8bb61"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429895145","pubTimestamp":1713888720,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Corcept Therapeutics Incorporated CORT announced positive data from one part of the pivotal phase III GRACE study, which evaluated its lead pipeline candidate, relacorilant, for treating patients with all etiologies of endogenous Cushing’s syndrome.The GRACE study consists of two parts. The above mentioned data was from the open-label portion of the study in which patients with Cushing’s syndrome and either hypertension, hyperglycemia or both were treated with relacorilant for a period of 22 weeks.Data from the open-label phase of the study showed that treatment with relacorilant led to clinically meaningful and statistically significant improvements in hypertension, hyperglycemia as well as other key secondary and exploratory endpoints.Per the company, patients who experienced pre-specified improvements in either or both symptoms were allowed to enter the GRACE study’s randomized withdrawal phase, in which half of the patients were treated with relacorilant while the other half was gi","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CORT":"Corcept医疗","BK4532":"文艺复兴科技持仓","ANIP":"ANI Pharmaceuticals, Inc.","BK4139":"生物科技","ADMA":"ADMA Biologics Inc","LGND":"Ligand Pharmaceuticals Inc.","BK4007":"制药"},"translate_title":"Corcept(CORT)公布库欣综合征研究的阳性数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1,"ANIP":1,"CORT":1,"LGND":1},"content_text":"Corcept Therapeutics Incorporated CORT announced positive data from one part of the pivotal phase III GRACE study, which evaluated its lead pipeline candidate, relacorilant, for treating patients with all etiologies of endogenous Cushing’s syndrome.\nThe GRACE study consists of two parts. The above mentioned data was from the open-label portion of the study in which patients with Cushing’s syndrome and either hypertension, hyperglycemia or both were treated with relacorilant for a period of 22 weeks.\nData from the open-label phase of the study showed that treatment with relacorilant led to clinically meaningful and statistically significant improvements in hypertension, hyperglycemia as well as other key secondary and exploratory endpoints.\nPer the company, patients who experienced pre-specified improvements in either or both symptoms were allowed to enter the GRACE study’s randomized withdrawal phase, in which half of the patients were treated with relacorilant while the other half was given placebo for a period of 12 weeks.\nThe primary endpoint of the GRACE study is to see the maintenance of blood pressure control in the randomized withdrawal phase, while maintenance of glycemic control was a key secondary endpoint.\nA new drug application for relacorilant in Cushing’s syndrome is likely to be submitted later in the second quarter of 2024.\nRelacorilant enjoys orphan drug designation for the treatment of Cushing’s syndrome both in the United States and the European Union.\nShares of Corcept have plunged 31.3% year to date compared with the industry’s decline of 12.8%.\nImage Source: Zacks Investment Research\nThis month has been a positive one for Corcept as it completed enrollment in several studies on relacorilant targeting other indications.\nEarlier this month, the company completed enrollment in the GRADIENT study, which is evaluating relacorilant for treating patients whose Cushing’s syndrome is caused by adrenal adenoma. Data from the same is expected in the fourth quarter of 2024.\nAlso, during the ongoing month, the company completed enrollment in the phase III ROSELLA study, which is investigating relacorilant in combination with Abraxane (nab-paclitaxel) for treating patients with recurrent, platinum-resistant ovarian cancer.\nData from the ROSELLA study is expected by 2024-end.\nMeanwhile, a phase Ib study is evaluating relacorilant in combination with Merck’s PD-1 checkpoint inhibitor, Keytruda (pembrolizumab), for treating patients with adrenal cancer with cortisol excess completed enrolment. Data from the study is expected in mid-2024.\nZacks Rank & Other Stocks to Consider\nCorcept currently sports a Zacks Rank #1 (Strong Buy).\nSome other top-ranked stocks in the healthcare sector are ADMA Biologics, Inc. ADMA, Ligand Pharmaceuticals Incorporated LGND and ANI Pharmaceuticals, Inc. ANIP, each sporting a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for ADMA Biologics’ 2024 earnings per share have improved from 22 cents to 30 cents. Year to date, shares of ADMA have rallied 37.2%.\nADMA’s earnings beat estimates in three of the trailing four quarters and met the same once, the average surprise being 85.00%.\nIn the past 60 days, estimates for Ligand’s 2024 earnings per share have improved from $4.42 to $4.56. Year to date, shares of LGND have decreased 4%.\nEarnings of LGND beat estimates in each of the trailing four quarters, the average surprise being 84.81%.\nIn the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.12 to $4.43. Year to date, shares of ANIP have jumped 19%.\nEarnings of ANIP beat estimates in each of the trailing four quarters, the average surprise being 109.06%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nLigand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report\nCorcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report\nANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report\nADMA Biologics Inc (ADMA) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429895145"}